Ehrhardt MJ, et al. - Given the hypothesized role of TP53 mutation-related gene-environment interactions in anthracycline-associated risk for subsequent breast cancer in childhood cancer survivors, researchers sought to characterize treatment/genetic risks and the impact of screening for breast cancer in the St Jude Lifetime Cohort. Sixty-eight breast cancers developed in 56 of 1,467 women at a median age of 38.6 (range, 24.5 to 53.0) years. Findings suggest an association of higher doses of anthracyclines with increased risk of breast cancer; this association was noted independent of mutations in known cancer predisposition genes. Breast cancers less likely to require chemotherapy were identified with surveillance imaging vs physical findings.